Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
- Conditions
- Neurotrophic Keratopathy
- Interventions
- Drug: OC-01 (varenicline) nasal spray 1.2 mg/mlDrug: Placebo (vehicle) nasal spray
- Registration Number
- NCT04957758
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Brief Summary
The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray as compared to placebo nasal spray for mean change from baseline in corneal fluorescein staining in subjects with Stage 1 (corneal epithelial hyperplasia/punctate keratopathy) neurotrophic keratopathy (NK) in one or both eyes.
- Detailed Description
Protocol OPP-102 is a Phase 2, multicenter, randomized, controlled, double- masked study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray in subjects with NK. Approximately 100 subjects at least 18 years of age with a physicians' diagnosis of Stage 1 NK as defined by the Mackie Criteria and meeting all other study eligibility criteria will be randomized 1:1 and will receive OC-01 (varenicline)/ nasal spray or placebo nasal spray for 8 weeks three times daily (TID) as follows:
* OC-01 (varenicline) nasal spray, 1.2 mg/mL
* Placebo (vehicle control) nasal spray All doses will be delivered as a 50 microliter (ยตL) nasal spray.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 113
- Be at least 18 years of age at Visit 1.
- Patients with Stage 1 (corneal epithelial hyperplasia/punctate keratopathy) NK in one or both eyes, as defined by the Mackie Criteria.
- Evidence of decreased corneal sensitivity (โค 4 cm using the Cochet-Bonnet aesthesiometer) in at least 1 corneal quadrant.
- Schirmer's test without anesthesia โฅ3 mm/ 5 minutes in the affected eye.
- If a female is of childbearing potential, they must: use an acceptable means of birth control (acceptable methods of contraception include hormonal - oral, implantable, injectable, or transdermal contraceptives, mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom, IUD, or surgical sterilization of partner), and have a negative urine pregnancy test on Day 1.
- Have Stage 2 or Stage 3 NK affecting one or both eyes.
- Have ocular graft versus host disease or Stevens-Johnson syndrome.
- Have any active ocular infection (COVID-19 conjunctivitis, bacterial, viral, fungal, or protozoal) or active ocular inflammation not related to NK in the affected eye.
- Be currently receiving autologous serum tears, amniotic membrane, cenegermin, fresh frozen plasma or cord blood derivative tears.
- Have severe blepharitis and/or severe meibomian gland disease in the study eye.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description OC-01 (varenicline) nasal spray, 1.2 mg/mL OC-01 (varenicline) nasal spray 1.2 mg/ml OC-01 (varenicline) nasal spray, 1.2 mg/mL Placebo (vehicle control) nasal spray Placebo (vehicle) nasal spray Placebo (vehicle control) nasal spray
- Primary Outcome Measures
Name Time Method Mean Change From Baseline in Corneal Fluorescein Staining 8 weeks Corneal Fluorescein Staining was measured utilizing the Modified Oxford Grading scale. Scores range from a minimum of 0 (no staining) to a maximum of 5. A higher score indicates a worse outcome. The study eye is defined as the eye with the worst staining grade (if both eyes are eligible).
- Secondary Outcome Measures
Name Time Method Mean Change From Baseline in Visual Acuity at Week 8 8 weeks Best Corrected Visual Acuity was assessed based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. ETDRS letters score range from 0 to 100 letters at each assessment.
A higher score in ETDRS letters indicates a better outcome. A positive change from Baseline in ETDRS letter score indicates an improvement in visual acuity.
Trial Locations
- Locations (31)
Danbury, Connecticut
๐บ๐ธDanbury, Connecticut, United States
Boston Massachusetts
๐บ๐ธBoston, Massachusetts, United States
Houston Texas
๐บ๐ธHouston, Texas, United States
Dothan Alabama
๐บ๐ธDothan, Alabama, United States
Irvine, California
๐บ๐ธIrvine, California, United States
Mission Hills California
๐บ๐ธMission Hills, California, United States
Los Angeles California
๐บ๐ธLos Angeles, California, United States
Littleton, Colorado
๐บ๐ธLittleton, Colorado, United States
Longmont, Colorado
๐บ๐ธLongmont, Colorado, United States
Brandon, Florida
๐บ๐ธBrandon, Florida, United States
Miami Florida
๐บ๐ธMiami, Florida, United States
Jacksonville Florida
๐บ๐ธJacksonville, Florida, United States
Brandon Florida
๐บ๐ธBrandon, Florida, United States
Urbana Illinois
๐บ๐ธUrbana, Illinois, United States
Atlanta, Georgia
๐บ๐ธAtlanta, Georgia, United States
Hoffman Estates, Illinois
๐บ๐ธHoffman Estates, Illinois, United States
Bowie, Maryland
๐บ๐ธBowie, Maryland, United States
Henderson Nevada
๐บ๐ธHenderson, Nevada, United States
Babylon New York
๐บ๐ธBabylon, New York, United States
New York NY
๐บ๐ธNew York, New York, United States
York, Pennsylvania
๐บ๐ธYork, Pennsylvania, United States
Katy, Texas
๐บ๐ธKaty, Texas, United States
Lynchburg Virginia
๐บ๐ธLynchburg, Virginia, United States
Seattle Washington
๐บ๐ธSeattle, Washington, United States
Dover New Jersey
๐บ๐ธDover, New Jersey, United States
Bloomfield, New Jersey
๐บ๐ธBloomfield, New Jersey, United States
Union Kentucky
๐บ๐ธEdgewood, Kentucky, United States
Aurora Colorado
๐บ๐ธAurora, Colorado, United States
Louisville KY
๐บ๐ธLouisville, Kentucky, United States
San Antonio Texas
๐บ๐ธSan Antonio, Texas, United States
Kansas City Missouri
๐บ๐ธKansas City, Missouri, United States